Man Group plc Buys Shares of 108,250 Cellebrite DI Ltd. (NASDAQ:CLBT)

Man Group plc acquired a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 108,250 shares of the company's stock, valued at approximately $2,385,000. Man Group plc owned 0.05% of Cellebrite DI as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. Gen Wealth Partners Inc purchased a new stake in Cellebrite DI in the 4th quarter valued at about $85,000. NewEdge Advisors LLC increased its position in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the last quarter. R Squared Ltd acquired a new position in Cellebrite DI during the fourth quarter worth approximately $100,000. Polen Capital Management LLC purchased a new position in Cellebrite DI during the fourth quarter worth approximately $222,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI in the 4th quarter valued at $234,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Price Performance

CLBT traded down $0.18 during trading hours on Wednesday, reaching $16.98. 140,918 shares of the stock traded hands, compared to its average volume of 1,456,390. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The company has a market cap of $4.07 billion, a price-to-earnings ratio of -12.21, a PEG ratio of 4.27 and a beta of 1.44. The firm's fifty day simple moving average is $18.84 and its two-hundred day simple moving average is $20.17.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The company had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. During the same period in the prior year, the company posted $0.08 EPS. The firm's revenue for the quarter was up 20.0% on a year-over-year basis. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on CLBT. Needham & Company LLC reduced their target price on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Lake Street Capital raised their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. decreased their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.